STRO · Sutro Biopharma, Inc. · Documents

$9.20 -0.74 (-7.44%) At close · Nov 5

Russell 2000 member Rebalance outlook locked

Market Cap

$153.71M

16.58M

Volume · Nov 5 771.86K Avg daily vol (3M) 319.6K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $102.48M up 65.2% 10-K filed Mar 23, 2026 Quarterly report FY2026 Q2 Revenue $9.84M down 84.6% 10-Q filed Aug 12, 2026 Latest results Financial results 8-K filed Aug 12, 2026

2026

Aug 12

Current report 8-K

Financial results, Regulation FD disclosure AI summary on its way

Aug 12

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $9.84M ▼ 84.6% Net loss $38.53M Diluted EPS -$2.33

Jun 8

Current report 8-K Events of Jun 5

Shareholder vote results AI summary on its way

Jun 5

Investor event

2026 Annual Meeting of Stockholders AI summary on its way

Jun 4

Investor event

Jefferies Global Healthcare Conference AI summary on its way

May 14

Current report 8-K

Financial results AI summary on its way

May 14

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Revenue $14.52M ▼ 16.5% Net loss $38.48M Diluted EPS -$2.94

Apr 22

Proxy statement DEF 14A Meeting Jun 5, 2026

Proxy statement AI summary on its way

Apr 22

Annual report to holders ARS

Annual report to holders AI summary on its way

Apr 22

Proxy statement DEFA14A

Proxy statement AI summary on its way

Mar 23

Current report 8-K

Ended a material agreement, Financial results AI summary on its way

Mar 23

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $102.48M ▲ 65.2% Net loss $191.09M Diluted EPS -$22.49

Mar 23

Registration statement S-3

Registration statement AI summary on its way

Feb 10

Current report 8-K Events of Feb 9

Entered into a material agreement, Regulation FD disclosure AI summary on its way

2025

Dec 17

Current report 8-K

Other events

Dec 3

Current report 8-K Events of Dec 1

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

Nov 6

Current report 8-K

Financial results

Nov 6

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Revenue $9.69M ▲ 13.8% Net loss $56.86M Diluted EPS -$0.67

Sep 29

Current report 8-K

Exit or restructuring costs

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Revenue $63.75M ▲ 148.0% Net loss $11.5M Diluted EPS -$0.14

Jun 25

Current report 8-K Events of Jun 20

Delisting notice or listing transfer

Jun 10

Current report 8-K Events of Jun 6

Shareholder vote results

Jun 2

Current report 8-K

Director or officer change, or executive pay

May 8

Current report 8-K

Financial results

May 8

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $17.4M ▲ 33.8% Net loss $75.97M Diluted EPS -$0.91

Apr 25

Proxy statement DEF 14A Meeting Jun 6, 2025

Proxy statement

Apr 25

Annual report to holders ARS

Annual report to holders

Apr 25

Proxy statement DEFA14A

Proxy statement

Apr 14

Current report 8-K Events of Apr 10

Director or officer change, or executive pay

Apr 14

Proxy statement PRE 14A Meeting Jun 6, 2025

Proxy statement

Mar 13

Current report 8-K

Financial results, Exit or restructuring costs, Director or officer change, or executive pay

Mar 13

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $62.04M ▼ 59.6% Net loss $227.46M Diluted EPS -$2.96

2024

Dec 10

Current report 8-K

Other events

Nov 13

Current report 8-K

Financial results

Nov 13

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $8.52M ▼ 49.7% Net loss $48.79M Diluted EPS -$0.59

Aug 13

Current report 8-K

Financial results

Aug 13

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $25.71M ▲ 146.9% Net loss $48.02M Diluted EPS -$0.59

Aug 12

Current report 8-K Events of Aug 8

Director or officer change, or executive pay

Jun 10

Current report 8-K Events of Jun 6

Shareholder vote results

May 17

Proxy statement DEFA14A

Proxy statement

May 13

Current report 8-K

Financial results

May 13

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $13.01M ▲ 2.6% Net loss $58.21M Diluted EPS -$0.95

Apr 26

Proxy statement DEF 14A Meeting Jun 6, 2024

Proxy statement

Apr 26

Annual report to holders ARS

Annual report to holders

Apr 26

Proxy statement DEFA14A

Proxy statement

Apr 2

Current report 8-K Events of Mar 29

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Apr 2

Current report 8-K

Entered into a material agreement

Mar 25

Current report 8-K

Financial results

Mar 25

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $153.73M ▲ 126.8% Net loss $106.79M Diluted EPS -$1.78

Showing 1–50 of 133 documents

Key facts CIK 1382101 CUSIP 869367201 13F (30d) 31 filings 19 filers Visit website Investor relations